Volume 26, Issue 6 pp. 946-957
REVIEW ARTICLE

Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management

Will Thomas

Corresponding Author

Will Thomas

Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Correspondence

Will Thomas, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, United Kingdom.

Email: [email protected]

Search for more papers by this author
Kate Downes

Kate Downes

East Midlands and East of England Genomic Laboratory Hub, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Department of Haematology, University of Cambridge, Cambridge, UK

Search for more papers by this author
Michael J. R. Desborough

Michael J. R. Desborough

Haemostasis and Thrombosis Centre, Guy’s and St Thomas' Hospital NHS Foundation Trust, London, UK

Search for more papers by this author
First published: 23 October 2020
Citations: 38

Abstract

Bleeding of unknown cause (BUC), also known as unclassified bleeding disorders (UBD), has been defined as a clear bleeding tendency in the presence of normal haemostatic tests. There are challenges in the diagnosis and management of these patients. BUC/UBD encompasses a heterogenous group of disorders which may include undiagnosed rare monogenic diseases, polygenic reasons for bleeding; and patients without a clear bleeding disorder but with a previous bleeding event. Nevertheless, these patients may have heavy menstrual bleeding or be at risk of bleeding when undergoing surgical procedures, or childbirth; optimizing haemostasis and establishing a mode of inheritance is important to minimize morbidity. The bleeding score has been used to clinically assess and describe these patients, but its value remains uncertain. In addition, accurate distinction between normal and pathological bleeding remains difficult. Several studies have investigated cohorts of these patients using research haemostasis tests, including thrombin generation and fibrinolytic assays, yet no clear characteristics have consistently emerged. Thus far, detailed genetic analysis of these patients has not been fruitful in unravelling the cause of bleeding. There is a need for standardization of diagnosis and management guidelines for these patients. This review gives an overview of this field with some suggestions for future research.

DISCLOSURES

WT—advisory boards for Daiichi Sankyo, Ablynx and Sanofi, speaking fees from Takeda, Bayer, Pfizer and support to attend the ISTH Congress by NovoNordisk. MD— advisory boards for Takeda and Portola. KD has no relevant conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.